{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-032003","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2025-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.349071+00:00","generated_at":"2026-05-26T06:58:19.844574+00:00","sec_items":["1.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Verrica enters lender waiver of going concern covenants for FY2024, Q1 2025","bullets":["Lenders waive covenant requiring no going concern qualification in Dec 2024 and Mar 2025 financials.","Waiver is with OrbiMed Royalty & Credit Opportunities IV, LP under Credit Agreement dated July 2023.","Remaining terms of Credit Agreement unchanged; waiver filed with 10-K.","This indicates auditor likely issued going concern opinion, signaling potential financial distress."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-032003","json":"https://secwatch.observer/filing/0001193125-25-032003.json","markdown":"https://secwatch.observer/filing/0001193125-25-032003.md","text":"https://secwatch.observer/filing/0001193125-25-032003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525032003/0001193125-25-032003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525032003/d812932d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:58:19.844574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}